Perrigo €1.6bn row is ‘a tax 101’ dispute

A demand that drugs company Perrigo pay Revenue €1.6bn in a dispute over tax involving its 2013 acquisition of Elan and the multiple sclerosis drug Tysabri is a straightforward “tax 101” row, experts have said.

Nonetheless, the issue could be seen as a reminder for other multinationals still considering moving intellectual property into Ireland about the potential for large tax disputes.